Activation of blood coagulation and fibrinolysis in vibration syndrome.
The pathophysiology of peripheral circulatory disturbance in patients presenting with vibration syndrome was studied from the viewpoint of blood coagulation. Plasma levels of fibronectin (FN), vitronectin (VN), thrombin-antithrombin III complex (TAT), and alpha 2-plasmin inhibitor-plasmin complex (PIC) were measured in 23 subjects who showed no evidence of vibration-induced white finger [VWF(-) group] and in 24 patients who presented with VWF [VWF(+) group]. In the VWF(-) group, plasma FN concentrations were elevated but plasma TAT and PIC levels were within the normal ranges. In the VWF(+) group, plasma FN concentrations were normal but plasma TAT and PIC levels were significantly elevated. In both groups, plasma VN concentrations were similar to those in normal controls. For purposes of comparison, 32 patients presenting with diabetes mellitus were also studied. They were divided into 2 groups, 13 subjects who showed no evidence of angiopathy [complication(-) group] and 19 patients who presented with angiopathy [complication(+) group]. In the complication(+) group, plasma TAT and PIC concentrations were significantly elevated, as in the VWF(+) group. These results suggest that in vibration syndrome, vibration, cold stimulus, or other factors first injure the vascular endothelium, resulting in a rise in plasma FN, and that in the VWF(+) group, augmentation of coagulation and fibrinolysis induces a state of compensated disseminated intravascular coagulation (DIC).
Shunto
R
R
First Department of Internal Medicine, School of Medicine, University of Tokushima, Japan.
Shirakami
A
A
Ohara
A
A
Toibana
N
N
Saito
S
S
D000328:Adult; D000368:Aged; D000933:Antifibrinolytic Agents / Q000097:blood; D000990:Antithrombin III / Q000032:analysis; D001779:Blood Coagulation Factors / Q000032:analysis*; D001798:Blood Proteins / Q000032:analysis; D005341:Fibrinolysin / Q000097:blood; D005342:Fibrinolysis; D005353:Fibronectins / Q000097:blood; D006023:Glycoproteins / Q000097:blood; D006801:Humans; D008875:Middle Aged; D010447:Peptide Hydrolases / Q000032:analysis; D011928:Raynaud Disease / Q000097:blood* / Q000209:etiology; D013577:Syndrome; D014732:Vibration / Q000009:adverse effects*; D019096:Vitronectin; D000979:alpha-2-Antiplasmin
D000933:Antifibrinolytic Agents; D001779:Blood Coagulation Factors; D001798:Blood Proteins; D005353:Fibronectins; D006023:Glycoproteins; D019096:Vitronectin; D000979:alpha-2-Antiplasmin; C046193:antithrombin III-protease complex; C037742:plasmin-plasmin inhibitor complex; D000990:Antithrombin III; D010447:Peptide Hydrolases; D005341:Fibrinolysin